Pathology Diagnostics Ltd Publish First White Paper in Series - The Use of Immunohistochemistry in Biomarker Research and Clinical Trials
The white paper, "The Use of Immunohistochemistry in Biomarker Research and Clinical Trials" is to be the first of a series of white papers published by Pathology Diagnostics over the next six months. - November 04, 2014
Pathology Diagnostics Ltd (PDL) Works Hand in Hand with Grants4Growth
Pathology Diagnostics Ltd is a highly successful SME which has recently expanded its facilities by moving to Stirling House business centre to a bespoke state-of-the-art pathology laboratory five times larger than its previous premises. As part of the company investment in the new facility, senior... - September 14, 2014
Pathology Diagnostics Ltd (PDL) Company Growth Leads to Significant Premises Expansion
Pathology Diagnostics Ltd has experienced recent company growth in size and structure, moving to new premises with state of the art laboratory facilities in May 2012 – since then acquiring several more large office spaces, meeting rooms and conference room facilities (to see more please go to... - September 13, 2014
Pathology Diagnostics Ltd (PDL) Wins Prestigious Biomedical Catalyst (BMC) Scheme Award
Pathology Diagnostics Ltd is one of the earliest SME recipients of the £180 million Technology Strategy Board (the UK’s Innovation Agency) Biomedical Catalyst funding programme; winning a Biomedical Catalyst feasibility award in the second round of the BMC scheme in December 2012. The... - September 12, 2014
Pathology Diagnostics Ltd Contributes as Expert Advisor to Groundbreaking Medical Research Council (MRC) Review of UK Molecular Pathology Services
The MRC has recently published a thought provoking and comprehensive review of molecular pathology capabilities in the United Kingdom in R&D and healthcare. The UK government and research charities (TSB, MRC, NIHR, CRUK, Arthritis UK) are collectively investing £200 million in the field of molecular pathology via the Stratified Medicine Innovation Platform (SMIP). Pathology Diagnostics Ltd lent their expertise as expert advisors to the review. - August 29, 2014
Pathology Diagnostics Ltd (PDL) Launches New Immunofluorescence Capabilities
Pathology Diagnostics has embraced the invaluably powerful technique of immunofluorescence (IMF); utilising fluorescent-labelled antibodies to detect specific target antigens. - July 11, 2014
Pathology Diagnostics Ltd.'s (PDL) Presence at Dako Symposium Strengthens Industry Connections
Senior technical management staff from Pathology Diagnostics attended the recent DakoLink-UP Scientific Symposium held in York in June 2014. Their presence strengthened connections already in place with Dako staff, and highlighted similarities in quality control and auditing needs with NHS... - July 05, 2014
Pathology Diagnostics Ltd (PDL) Biomarker Test Portfolio and Advanced Staining Capabilities Show CAGR of 50%
Due to the recent rapid growth of Pathology Diagnostics Ltd (PDL), the advanced laboratory staining biomarker test portfolio of the organisation has grown at an extremely impressive rate, with the number of biomarkers validated now reaching over 370 for immunohistochemistry (IHC) and... - June 27, 2014
Pathology Diagnostics Ltd (PDL) Launches Social Media Presence Online
Having already established itself as one of the leaders in its industry, Pathology Diagnostics is continuing to grow from strength to strength – evolving into a formidable organisation within its market space. Wanting to showcase its employee expertise (both academic and industry-applied) and... - June 22, 2014